These clinical and preclinical findings provide rationale for therapies to increase therapeutic index of aPD-1 therapy by diminishing presence of T cell-suppressive myelomonocytic cells to improve outcomes for patients with refractory disease.
CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors
Amanda Poissonnier·Lisa M. Coussens·Eivind Valen Egeland·Byung Park·Nell Kirchberger·Shivaani Kummar·Ingrid A. Mayer·Tiziana Cotechini·Nicky A. Beelen·Motomi Mori·Amy DeLuca·Kimberly Blackwell·H. S. Rugo·Dhaarini Murugan·Tina Kim·Yun Yu·Shamilene Sivagnanam·E. Shelley Hwang·Wesley Horton